|Common transplant drug inhibits breast cancer growth, UNC laboratory study shows|
|Thursday, May 26, 2011|
Tacrolimus, a drug that is commonly used to prevent organ transplantation rejection, inhibits breast cancer growth in pre-clinical studies. The finding from UNC scientists was reported in the May 26th Public Library of Science.
Nancy Klauber-DeMore, MD, associate professor of surgery, said, " We now have a rationale for performing human clinical trials to determine if Tacrolimus reduces breast cancer growth in humans. Since Tacrolimus is already an FDA-approved drug, the safety and toxicity profile is known, which means that Tacrolimus could potentially go directly into a later stage clinical trial."
For full release